Terms ending in 2038
Every in-force patent on Tesaro, Inc.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,091,459 | Niraparib Compositions In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 11,673,877 | Niraparib Compositions In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 12,415,855 | Methods of Treating Cancer with ANTI-PD-1 Antibodies In force · High confidence | Tesaro, Inc. | In force | High confidence | |
| US 11,161,834 | Methods of Manufacturing of Niraparib In force · High confidence | Tesaro, Inc. | In force | High confidence | |
| US 11,629,137 | Methods of Manufacturing of Niraparib In force · High confidence | Tesaro, Inc. | In force | High confidence | |
| US 11,622,961 | Combination Therapies for Treating Cancer In force · High confidence | Tesaro, Inc. | In force | High confidence | |
| US 11,155,624 | Antibodies Directed Against Programmed Death- 1 (PD-1) In force · High confidence | Anaptysbio, Inc. and Tesaro, Inc. | In force | High confidence | |
| US 11,407,830 | Methods of Treating Cancer with ANTI-PD-1 Antibodies In force · High confidence | Tesaro, Inc. | In force | High confidence | |
| US 10,927,077 | Process for Preparing Intermediate of Anti-Tumor Drug Niraparib and Intermediate Thereof In force · High confidence | Tesaro, Inc. | In force | High confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
7 of these are in force and held by Tesaro, Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.